Nelivaptan

Nelivaptan (INN), codenamed SSR-149,415, is a selective and orally active non-peptide vasopressin receptor antagonist selective for the V1b subtype. The drug had entered clinical trials for treatment of anxiety and depression. In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.